Publication | Closed Access
ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers
17
Citations
0
References
2016
Year
Antibody–drug ConjugateDrug TargetingMedicineNovel PyrrolobenzodiazepinePharmacologyTumor TargetingAnti-cancer AgentTargeted TherapyCancer TreatmentOncologyRadiation OncologyCancer Research
No additional data available for this publication yet. Check back later!